These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24855208)

  • 1. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia.
    Sasca D; Hähnel PS; Szybinski J; Khawaja K; Kriege O; Pante SV; Bullinger L; Strand S; Strand D; Theobald M; Kindler T
    Blood; 2014 Jul; 124(1):121-33. PubMed ID: 24855208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.
    Li L; Osdal T; Ho Y; Chun S; McDonald T; Agarwal P; Lin A; Chu S; Qi J; Li L; Hsieh YT; Dos Santos C; Yuan H; Ha TQ; Popa M; Hovland R; Bruserud Ø; Gjertsen BT; Kuo YH; Chen W; Lain S; McCormack E; Bhatia R
    Cell Stem Cell; 2014 Oct; 15(4):431-446. PubMed ID: 25280219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia.
    Zhou L; Wang Q; Chen X; Fu L; Zhang X; Wang L; Deng A; Li D; Liu J; Lv N; Wang L; Li Y; Liu D; Yu L; Dou L
    Exp Hematol; 2017 Feb; 46():62-69. PubMed ID: 27725192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
    Li L; Bhatia R
    Curr Opin Hematol; 2015 Jul; 22(4):324-9. PubMed ID: 26049753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
    Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
    Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.
    Sun YM; Wang WT; Zeng ZC; Chen TQ; Han C; Pan Q; Huang W; Fang K; Sun LY; Zhou YF; Luo XQ; Luo C; Du X; Chen YQ
    Blood; 2019 Oct; 134(18):1533-1546. PubMed ID: 31387917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BEX1 acts as a tumor suppressor in acute myeloid leukemia.
    Lindblad O; Li T; Su X; Sun J; Kabir NN; Levander F; Zhao H; Lu G; Rönnstrand L; Kazi JU
    Oncotarget; 2015 Aug; 6(25):21395-405. PubMed ID: 26046670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia.
    Tian WL; Guo R; Wang F; Jiang ZX; Tang P; Huang YM; Sun L
    Exp Cell Res; 2018 Apr; 365(2):185-193. PubMed ID: 29501566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
    Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
    Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
    Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
    Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
    Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.
    Irish JM; Anensen N; Hovland R; Skavland J; Børresen-Dale AL; Bruserud O; Nolan GP; Gjertsen BT
    Blood; 2007 Mar; 109(6):2589-96. PubMed ID: 17105820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
    Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
    Elife; 2016 Nov; 5():. PubMed ID: 27879203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.
    Wobus M; Bornhäuser M; Jacobi A; Kräter M; Otto O; Ortlepp C; Guck J; Ehninger G; Thiede C; Oelschlägel U
    Oncotarget; 2015 Nov; 6(36):38804-15. PubMed ID: 26462154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
    Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
    BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.